Categories
All news

Hepatitis C Drugs Market 2020-2027 | The demand for the Market will Drastically Increase In The Future


Hepatitis C is a major liver disease, and it has become a global burden. Moreover, key players are focused on developing new drugs for the treatment of hepatitis C. Increasing launches of new drugs is expected to drive the hepatitis C drugs market growth. For instance, in 2019, The AbbVie Inc. company received the U.S. Food and Drug Administration approval for Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children of age group of 12 to 17.

Moreover, in 2018, Nacto Pharma ltd launched a drug with brand name as Hepcinat Plus for the treatment of hepatitis C disease. This drug is generic form and fixed combination of Sofosbuvir-Declatasvir tablet. The company launched this drug at a retail price of US$ 246.1 for 28 tablets.

Furthermore, in 2018, Gilead Sciences Company launched generic versions of Harvoni and Epclusa, which was valued at US$ 24,000 for full course of therapy. The launch of these drugs helped to resolve the issue related to high cost of branded drugs, which is around US$ 100,000 for full course of therapy.

Request for Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1489

Moreover, in 2016, Organisation for Economic Co-operation and Development performed an economic analysis in Australia used a mathematical model, which was based on the WHO strategy’s targets. On the basis of the results of this analysis, in March 2016, the Australian Pharmaceutical Benefits scheme listed a number of DAAs (Direct-acting antivirals) for the treatment of hepatitis C, wherein it covers majority of the drug costs. As a result of this scheme, from March to September 2016, it was estimated that 25,900 number of people underwent treatment, which represents 11% of people with HCV infection.

Apply Promo Code “STAYHOME” and Get Instant Discount of USD 1000

If you purchase the report this year:

 Flat 20% instant discount

 25% discount on 2nd report

 15 % free customization

Buy This Complete A Business Report @: https://www.coherentmarketinsights.com/insight/buy-now/1489

Increasing prevalence of hepatitis C is expected to drive growth of hepatitis C drugs market over the forecast period. For instance, in 2018, according to the Centers for Disease Control and Prevention (CDC), around 3.9 million of U.S. population suffered from hepatitis C. Hepatitis C virus (HCV) infection is a commonly found blood borne infection in the U.S.

Moreover, in Canada, 246,000 number of Canada population suffered with HCV disease in 2017, wherein around 44% were unaware about HCV infection.

However, high cost of hepatitis C treatment is expected to hamper growth of the hepatitis C drugs market during the forecast period. For instance, in the U.S., a 12-week course of Sovaldi costs around US$ 84,000, where one pill costs around US$ 1,000. Similarly, Olysio drug costs around US$ 23,600 per month of hepatitis C treatment and treatment period for this drug was around 24-48 weeks.

Contacts Us:
Direct Line: +1-206-701-6702 (US)
Web: https://www.coherentmarketinsights.com

https://insurancejust.com/